This inventor holds 4 USPTO granted patents. Top assignees: Meiji Seika Kaisha, Ltd., Meija Seika Co., Ltd.. Active years: 1976-1978.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Chigasaki, JA (1976)
- Chigasaki, JP (1978)
Company Filing History:
Years Active: 1976-1978
Title: The Innovations of Takeshi Mayama
Introduction
Takeshi Mayama is a notable inventor based in Chigasaki, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of stable amorphous macrolide antibiotics. With a total of 4 patents to his name, Mayama's work has had a considerable impact on drug formulation and delivery.
Latest Patents
One of Mayama's latest patents is titled "Process for preparation of stable amorphous macrolide antibiotic solids." This innovative process involves dissolving a macrolide antibiotic and a cellulose polymer in a volatile organic solvent, followed by spray drying the resulting solution to create stable amorphous solids. Another significant patent is "Process for preparing preparations for oral administration," which focuses on eliminating the bitter taste of medications. This process includes either dissolving a bitter taste-masking substance at a high concentration or kneading a solution with the active ingredient, ultimately leading to a palatable oral preparation.
Career Highlights
Throughout his career, Takeshi Mayama has worked with prominent companies such as Meiji Seika Kaisha, Ltd. and Meiji Seika Co., Ltd. His experience in these organizations has allowed him to refine his skills and contribute to groundbreaking pharmaceutical innovations.
Collaborations
Mayama has collaborated with esteemed colleagues, including Toshiyuki Kobayashi and Akira Okada. These partnerships have fostered a creative environment that has led to the development of his notable patents.
Conclusion
Takeshi Mayama's contributions to the field of pharmaceuticals through his innovative patents demonstrate his commitment to improving drug formulations. His work continues to influence the industry and enhance patient care.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
